United Kingdom Multiomics Market Size, Share, Growth, and Industry Analysis, By Omics Type (Genomics, Transcriptomics, Proteomics, Metabolomics), By Application (Drug Discovery and Development, Precision Medicine and Personalized Therapy, Biomarker Identification, Clinical Diagnostics) and Forecast, 2026-2034

United Kingdom Multiomics Market Trends

Large-Scale Cohorts and Integrated Biological Data Are Reshaping Research Workflows

Multi-layer biological analysis is moving from relatively small experimental cohorts toward population-scale datasets containing millions of participant records and samples. Our Future Health reported more than 2 million recruited participants by January 2025, including over 1 million participants with biobanked blood samples, against a long-term recruitment objective of 5 million adults. This scale supports increasing integration of genetic, clinical, lifestyle and biomarker information.

Technology development is simultaneously shifting toward single-cell analysis, AI-assisted proteomics, high-throughput sequencing and computational integration. By September 2025, Our Future Health's research environment contained questionnaire information from 1,900,495 volunteers, while more than 2.5 million people had consented to the programme. These million-participant datasets strengthen requirements for scalable software, cloud analysis and multi-layer integration rather than isolated single-omics workflows.

United Kingdom Multiomics Market Drivers

Expansion of Population Genomics and Precision Research Infrastructure

Large national datasets are accelerating biological discovery and translational research. The 100,000 Genomes Project sequenced more than 100,000 genomes, while analysis involving over 4,000 individuals from more than 2,000 families showed whole-genome sequencing produced a new diagnosis for 25% of participants studied; 14% of those diagnoses involved variants that other non-whole-genome approaches could miss. Meanwhile, Our Future Health secured up to GBP 354 million in additional government funding in 2025, reinforcing infrastructure supporting data-intensive precision research.

United Kingdom Multiomics Market Restraints

Data Complexity, Privacy Requirements and Integration Costs Restrict Scaling

Multiomics workflows can combine 7 omics layers and millions of observations, creating substantial storage, harmonisation and computational requirements. Our Future Health's trusted research environment already contained information from almost 1.8 million people in June 2025, including 1,781,891 completed health and lifestyle questionnaires, following an increase of more than 200,000 records in one quarterly release. Scaling datasets of this magnitude increases requirements for secure computing, interoperability, quality control and governance.

United Kingdom Multiomics Market Opportunities

Precision Medicine and Integrated Biomarker Discovery Create Commercial Headroom

The UK's expanding cohort infrastructure creates opportunities across sequencing, proteomics, biomarker analytics and integrated software. More than 2.5 million volunteers had joined Our Future Health by July 2025 versus a target of up to 5 million, leaving approximately 2.5 million additional participant positions toward the programme objective. Combined genetic, health-record and biological information can support earlier disease detection, risk stratification and therapeutic research across increasingly large populations.

Challenges in United Kingdom Multiomics Market

Converting High-Dimensional Research Data into Reproducible Clinical Evidence

The central challenge is moving from datasets containing 100,000+ genomes and millions of longitudinal records toward clinically reproducible conclusions. Although whole-genome sequencing generated new diagnoses for 25% of participants in one 100,000 Genomes Project analysis, actionable interpretation varies by disease and evidence maturity. Integration across 7 omics categories, multiple clinical endpoints and heterogeneous analytical platforms therefore requires validated algorithms, standardised pipelines and robust longitudinal datasets.

United Kingdom Multiomics Market Segmentation

The market is segmented by Omics Type, Application, Technology, Offering and End User. Within supplied quantitative categories, genomics accounts for approximately 28.08% of the 2026 omics-type value, while Drug Discovery and Development represents approximately 25.80% of the 2026 application value.

By Omics Type

Genomics is the largest omics-type segment, increasing from USD 57.69 million in 2025 to USD 67.05 million in 2026 and reaching USD 223.17 million by 2034, representing a 16.22% CAGR. Proteomics follows at USD 56.88 million in 2026 and USD 189.72 million by 2034.

Epigenomics and Microbiomics are the fastest-growing supplied categories, each recording 16.40% CAGR. Epigenomics rises from USD 20.11 million in 2026 to USD 67.78 million by 2034, while Microbiomics advances from USD 14.50 million to USD 48.88 million.

By Application

Drug Discovery and Development leads applications at USD 61.55 million in 2026, rising from USD 53.25 million in 2025 to USD 196.00 million by 2034, at a 15.58% CAGR. Precision Medicine and Personalized Therapy follows at USD 47.41 million in 2026.

Agriculture and Crop Research is the fastest-growing application with a 16.79% CAGR, increasing from USD 19.91 million in 2026 to USD 68.92 million by 2034. Clinical Diagnostics records 16.19% CAGR, while Infectious Disease Surveillance reaches 16.29% CAGR.

By Technology

Technology segmentation comprises 6 categories: Next-Generation Sequencing, Mass Spectrometry, Microarrays, Single-Cell Analysis, Real-Time PCR and Multiomics Integration Platforms. Quantified technology-level revenues and CAGRs were not supplied; consequently, no unsupported monetary allocation is applied across these 6 subsegments.

NGS benefits from established UK sequencing infrastructure exceeding 100,000 genomes, while mass spectrometry remains fundamental to proteomics and metabolomics. Single-cell and integration platforms increasingly address simultaneous analysis across 2 or more biological layers, but technology-level forecast CAGRs cannot be calculated from the supplied tables.

By Offering

The offering landscape comprises 3 categories—Software and Services, Instruments and Consumables. These offerings collectively support workflows spanning the 7 specified omics types and 8 applications, including sequencing, sample preparation, mass spectrometry, computational processing and biological interpretation.

No offering-level market values or CAGRs were supplied. Accordingly, the USD 238.76 million 2026 total and USD 787.92 million 2034 total are not redistributed among the 3 offering categories without supporting numerical evidence.

By End User

The end-user landscape contains 5 groups: Pharmaceutical and Biotechnology Companies, Academic and Research Institutions, Contract Research Organizations, Hospitals and Clinics, and Government and Public Health Agencies. Pharmaceutical research is supported by the application profile, where Drug Discovery and Development represents approximately 25.80% of quantified 2026 application revenue.

Academic, clinical and public-sector adoption is reinforced by national research cohorts exceeding 2.5 million consenting volunteers and historical sequencing infrastructure covering more than 100,000 genomes. End-user-specific revenue and CAGR figures were not supplied and are therefore not estimated.

United Kingdom Multiomics Market Outlook

London, Cambridge and Oxford form the UK's principal biomedical research corridor, supported by major universities, hospitals, pharmaceutical R&D and genomics infrastructure. A defensible county-level percentage allocation of the USD 238.76 million 2026 national total cannot be calculated from the supplied dataset; therefore, regional shares are intentionally not fabricated. Recent investment illustrates concentration in the corridor: GSK announced a Cambridge R&D consolidation involving more than 1,000 scientists and approximately GBP 400 million of UK life-sciences investment over 3 years.

Outside the Golden Triangle, genomics infrastructure extends through NHS and national cohort programmes across England and the wider UK. Our Future Health exceeded 2.5 million volunteers nationally in 2025 and targets up to 5 million adults, while the 100,000 Genomes Project generated more than 100,000 genomes from 85,000+ participants. These programmes create distributed requirements for sample collection, sequencing, bioinformatics and clinical interpretation, although county-level monetary contributions remain unavailable.

Top players in United Kingdom Multiomics Market

• Illumina, Inc.
• Thermo Fisher Scientific Inc.
• Oxford Nanopore Technologies plc
• QIAGEN N.V.
• Agilent Technologies, Inc.
• Bruker Corporation
• Bio-Rad Laboratories, Inc.
• Standard BioTools Inc.
• 10x Genomics, Inc.
• BGI Genomics
• Pacific Biosciences
• Waters Corporation
• Revvity, Inc.

Top Two Companies

• Illumina, Inc.

Exact UK multiomics revenue share is not disclosed in the supplied dataset and is therefore not assigned an unsupported percentage. The company is positioned around high-throughput sequencing and associated informatics, addressing genomics-led workflows in a national environment where genomics represents approximately 28.08% of the quantified 2026 omics-type value. The addressable ecosystem includes 100,000+ historically sequenced genomes through Genomics England and population programmes targeting as many as 5 million participants, creating continued requirements for sequencing, interpretation and integrated biological analysis.

• Thermo Fisher Scientific Inc.

A verified UK-specific company percentage is not provided and is not estimated. Its competitive positioning spans sequencing-related laboratory workflows, mass spectrometry, consumables and analytical systems relevant to genomics, proteomics and metabolomics. Proteomics alone accounts for USD 56.88 million in 2026 and is forecast to reach USD 189.72 million by 2034, registering 16.25% CAGR. The breadth of instrumentation and laboratory technologies positions diversified suppliers to address multiple layers of the 7-category omics landscape, rather than depending on a single analytical modality.

Recent Developments in United Kingdom Multiomics Market

• 2026: GSK outlined a UK restructuring that includes moving more than 1,000 scientists to Cambridge and approximately GBP 400 million of life-sciences investment over 3 years, strengthening the country's translational R&D ecosystem.
• 2025: Our Future Health surpassed 2.5 million volunteers, crossing 50% of its targeted recruitment of up to 5 million UK adults.
• 2025: The UK Government announced up to GBP 354 million in additional funding for Our Future Health, supporting expansion of population-scale biomedical research infrastructure.
• 2025: Our Future Health opened its research resource after recruiting more than 2 million participants, including over 1 million with biobanked blood samples.
• 2025: The programme's June research release contained data from almost 1.8 million people, including 1,781,891 questionnaires, following the addition of more than 200,000 questionnaire records.

Research Methodology

The assessment uses 2025 as the base year, 2026 as the current year, historical analysis for 2022–2024, and forecasts through 2034. Supplied numerical tables were treated as mandatory primary inputs, including the USD 205.67 million 2025 base value, USD 238.76 million 2026 value, USD 787.92 million 2034 forecast and 16.12% CAGR. Segment percentages were calculated directly from supplied totals; external sources were used only for contextual production, cohort, infrastructure and development indicators. No company, technology, offering, end-user or county-level revenue share was fabricated where quantitative source data were unavailable.